Arax Advisory Partners
BEAM icon

Arax Advisory Partners’s Beam Therapeutics BEAM Stock Holding History

Arax Advisory Partners’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$17.6K Buy
512
+502
+5,020% +$15.2K ﹤0.01% 4047
2026
Q1 		$238 Sell
10
-65
-87% -$1.8K ﹤0.01% 3515
2025
Q4 		$2.08K Buy
+75
New +$1.91K ﹤0.01% 3244
2025
Q2 		– Sell
-30
Closed -$586 – 3049
2025
Q1 		$586 Hold
30
– – ﹤0.01% 2514
2024
Q4 		$744 Buy
+30
New +$766 ﹤0.01% 2235

Other funds holding BEAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Farallon Capital Management
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
ARK Investment Management
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
Nikko Asset Management Americas
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Arax Advisory Partners's BEAM Position: Q2 2026 in Review

Arax Advisory Partners increased its Beam Therapeutics (BEAM) stake by 5,020% in Q2 2026, buying an estimated $15.2K and bringing the position to 512 shares worth $17.6K. The position accounts for ﹤0.01% of the portfolio, ranked #4047.

Arax Advisory Partners first reported a position in BEAM in Q4 2024 and has held it in 5 quarters since. 277 funds tracked by Wall St. Rank hold BEAM as of Q2 2026.

  • Arax Advisory Partners held 512 shares of Beam Therapeutics worth $17.6K as of Q2 2026.
  • Arax Advisory Partners bought 502 Beam Therapeutics shares in Q2 2026, an estimated $15.2K.
  • Beam Therapeutics made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #4047 holding.
  • Arax Advisory Partners first reported a position in Beam Therapeutics in Q4 2024 and has held it in 5 quarters since.
  • 277 funds tracked by Wall St. Rank held Beam Therapeutics as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.